In addition, increased serum levels of other Th cytokines and chemokines were observed in the HER2-DC1 i.t. in combination with anti-HER2 antibodies treated group, and in immune mice that rejected secondary TUBO tumor challenge (online supplemental figures 1 and 2). This evidence concerns the gene ERBB2 and neoplasm.